|
Found 222 result(s) FROM 1963 pages containing the term 'fracture'.
Friday Mar 12, 2010
Long-term Bisphosphonate Use May Actually Increase Fracture Risk
The osteoporosis drugs may boost bone quantity at the expense of bone quality, eventually weakening users' bones...
Thursday Nov 05, 2009
TNFα Weakens Bones in Diabetes
High levels of TNF-α in diabetics accelerates cartilage loss, weakens bones, and slows fracture healing...
Thursday Aug 27, 2009
Study: Hip Fracture Rates On the Decline in Canada
Hip fracture rates in Canada have been declining since 1985, with a more rapid drop between 1996 and 2005...
Tuesday Aug 25, 2009
First RCTs Cast Doubt on Vertebroplasty Gains
The first 2 randomized, placebo-controlled trials of vertebroplasty for osteoporotic fractures show no significant benefits for the procedure...
Thursday Jul 09, 2009
Amgen's Denosumab Bests Zometa in Breast Cancer Patients
The first of three pivotal oncology trials comparing denosumab to Zometa in the advanced cancer setting meets primary and secondary endpoints...
Thursday Jun 11, 2009
RA Bone Changes May Offer New Treatment Target
Osteoporosis and erosions appear loosely linked in some RA patients...
Wednesday Jun 03, 2009
DHEA Intensifies Calcium, Vitamin D Effect on BMD
Adding DHEA to calcium and vitamin D significantly increases spine BMD in older women (but not in men) and might be a good thing, provided the women don't have family cancer risk and don't need to pass any sports doping tests...
Tuesday May 12, 2009
Obesity, Arthritis Blamed for Disability in Women
Females are at greater risk of obesity and arthritis than their male counterparts and these disabling conditions begin early and can rob women of their quality of life...
Monday Apr 20, 2009
Forteo May Help Mend Non-Healing Fractures
Subcutaneous daily injections of parathyroid hormone (teriparatide, Forteo, Eli Lilly and Co) may help heal painful non-union or delayed union fractures by stimulating bone stem cells...
Friday Mar 27, 2009
Fablyn® OK'ed in EU for Osteoporosis, Still on Hold in US
Pfizer-Ligand's Fablyn® (lasofoxifene) has been approved by European regulators, just months after failing to win FDA approval in the US...
Monday Mar 23, 2009
More Americans Need Vitamin D to Prevent Fractures
Daily vitamin D supplements of >400 IU/day can cut fracture risk by 19-20%, but more Americans are becoming vitamin D-deficient...
Monday Mar 02, 2009
Early Screening, Osteoporosis Treatment Needed to Reduce Hip Fracture Rates
Early osteoporosis screening and treatment are being pushed worldwide as orthopaedic surgeons try to stem the tide of hip fractures in aging populations...
Tuesday Feb 10, 2009
Each Osteoporotic Fracture Ups Death Risk
Women and men age 60 years or older who sustain a low-trauma osteoporotic fracture are at an increased risk of dying during the following 5 to 10 years...
Monday Feb 02, 2009
Rituximab B-Cell Depletion Stops JIA
Systemic onset JIA responded dramatically to B-cell depletion with rituximab...
Wednesday Jan 21, 2009
FDA Grounds Pfizer's Fablyn Osteoporosis Drug
Pfizer's Fablyn (lasofoxifene) is still on hold as FDA seeks more safety data...
Thursday Jan 15, 2009
Parkinson's Disease Puts Bones, Joints at Risk
The symptoms of Parkinson’s disease—tremors, rigidity in the joints, and balance problems—can lead to reduced bone mass and a greater risk of falls, resulting in heightened numbers of bone fractures and joint injuries…
Wednesday Jan 07, 2009
Study Links Osteoporosis Drugs to Jaw Trouble
People taking oral osteoporosis drugs may have a higher risk of developing jaw trouble than previously thought...
Monday Dec 15, 2008
Diabetes Drugs Double Fracture Risk
Long-term use of a popular class of oral diabetic drugs doubles the risk of fractures in women with type 2 diabetes...
Friday Dec 12, 2008
Cartilage Repair Moving from Bench to Bedside
Mosiacplasty may soon be the method of choice for orthopaedic surgeons treating small focal defects in cartilage, but stem cell-based cartilage repair is also moving stealthily down the pike...
Tuesday Dec 02, 2008
Medicaid DXA Cuts Jeopardize Osteoporosis Care
If Medicaid reimbursement cuts for dual X-ray absorptiometry (DXA) are not reversed, experts predict a surge in osteoporotic fractures that will raise costs far beyond the DXA cost savings...
Thursday Nov 13, 2008
H. pylori Suspected in Oral Bisphosphonate Intolerance, SSc Stomach Problems
Helicobacter pylori infects nearly half of patients who cannot tolerate oral bisphosphonates and over 80% of systemic sclerosis patients. Treating H. pylori might reduce GI problems and increase treatment options in these and other rheumatoid conditions...
Thursday Nov 13, 2008
Parathyroid Hormone Patch May Increase BMD and Adherence
A new patch that delivers parathyroid hormone (PTH) may increase spine and hip BMD and avoid some of the compliance issues seen with subcutaneous daily injections of PTH…
Thursday Oct 30, 2008
Merck, Japan Tobacco in Osteoporosis Drug Deal
Merck and Japan Tobacco announced a worldwide licensing agreement to develop and commercialize JTT-305, an investigational oral osteoanabolic agent for the treatment of osteoporosis...
Thursday Oct 23, 2008
Tamoxifen Cuts Fracture Risk
The breast cancer drug tamoxifen has been found to reduce the risk of osteoporotic fractures, but the protection against fractures diminshes after treatment with the drug ends…
Monday Oct 20, 2008
Bone Health Organizations Around the Globe Mark World Osteoporosis Day
October 20th is World Osteoporosis Day, which is the launch of a campaign to mobilize public opinion to generate change in osteoporosis healthcare policies…
Thursday Oct 16, 2008
Novartis Reports Once-Yearly Aclasta® Approved in EU to Treat Osteoporosis in Men; Label to Include Reduction of New Fractures Following Hip Fracture in Men and Postmenopausal Women
The European Commission followed the US FDA in approving once-yearly Aclasta for the treatment of osteoporosis in men who are at increased risk of fractures, and has broadened the drug’s label to include reduction of new fractures in men and postmenopausal women with osteoporosis who have recently suffered a hip fracture...
Thursday Oct 02, 2008
Vitamin C Protects Some Elderly Men From Bone Loss
Eating nutrient-rich fruits and vegetables can protect elderly men from the bone loss that leads to hip fractures…
Friday Sep 26, 2008
ASBMR Reports Show 68% Drop in Spinal Fractures With Denosumab, Stronger Effect on Bone Turnover Than With Alendronate, High Patient Preference
Studies reported at the 2008 ASBMR meeting showed that denosumab, which is given twice yearly, was as effective as the best competing agents at preventing osteoporotic fractures. Denosumab produced greater gains in BMD than alendronate and was preferred to once-weekly oral alendronate...
Thursday Sep 04, 2008
Scientists Discover How Osteoarthritis Destroys Cartilage
New discovery may lead to preventive treatment for osteoarthritis…
Thursday Aug 28, 2008
Experts Urge More Attention to Vitamin D in Rheumatoid Arthritis
Vitamin D not only helps prevent steroid-induced osteoporosis in rheumatoid arthritis but might also help reduce falls and modulate disease activity...
Thursday Aug 28, 2008
Mesoblast Reports Preclinical Study Shows Allogeneic Stem Cells in Ewes are Safe, Effective for Cervical Spine Fusion; Therapy May Receive Boost From US FDA’s Recent Alert of Life-Threatening Complications Associated With rhBMP in Cervical Spine Fusions
Mesoblast is currently in phase II clinical trials for fusion of the lumbar spine and, based on these new results, will extend its market opportunity to cover the entire spectrum of spinal fusion. Subject to FDA approval, Mesoblast's therapy will eliminate the need for autograft...
Monday Aug 25, 2008
Emisphere Reports Full Recruitment of Study Evaluating Eligen® Technology and Salmon Calcitonin on Vertebral Fractures in Postmenopausal Women
Emisphere Technologies announced that recruitment is finished for a randomized, double-blind, placebo-controlled, multicenter study of oral salmon calcitonin in the treatment of osteoporosis in postmenopausal women taking calcium and vitamin D...
Thursday Aug 21, 2008
Mesoblast Reports Stem Cells Regrow Knee Cartilage in Postmenopausal Ewes With OA; Repair Nonhealing Bones in Humans
Mesoblast, a regenerative medicine company developing treatments for orthopaedic conditions, announced successful preclinical trial results showing that its proprietary adult stem cells regenerated and regrew damaged knee cartilage...
Wednesday Aug 20, 2008
Zoledronic Acid Prevents Chemo-Induced Bone Loss in Premenopausal Women With Breast Cancer
As the population of breast cancer survivors grows, the risks of life after cancer treatment are becoming a major concern. One risk is bone loss caused by chemotherapy, and phase III data show that a dose of zoledronic acid every 3 months during chemotherapy can prevent this problem in premenopausal women with breast cancer...
Tuesday Aug 12, 2008
Powerful Antacid Drugs Raise Fracture Risk
Long-term use of proton pump inhibitors may elevate the risk of osteoporosis-related fractures…
Wednesday Aug 06, 2008
Statins May Help Bone Healing
Statins may improve bone healing, according to new research in an animal model of neurofibromatosis type 1 (NF1)…
Thursday Jul 17, 2008
Drugs to Build Bones May Weaken Them
A small group of people taking bisphosphonates for 5 or more years to treat osteoporosis have had their bones weakened by the drugs that are intended to promote better bone health…
Wednesday Jul 16, 2008
Amgen Reports Positive Top-Line Results for Denosumab Treatment of Bone Loss in Men With Nonmetastatic Prostate Cancer Undergoing Androgen Deprivation Therapy; Study Met Primary, Secondary Endpoints
The improvements in BMD were consistent with those seen in other denosumab studies evaluating BMD in women with breast cancer receiving aromatase inhibitor therapy and in postmenopausal women with low bone mass...
Thursday Jul 10, 2008
A List of Drugs That Increase Falling Risk
Many common prescription seizure medications, painkillers, and antidepressants may elevate the risk of falling among older patients...
Thursday Jul 03, 2008
Heel Ultrasound Improves Osteoporosis Diagnosis
A heel quantitative ultrasound coupled with an assessment of specific osteoporosis-related risk factors in patients can help doctors predict fracture risk and decide who would need further screening with dual-energy X-ray absorptiometry (DXA)…
Tuesday Jul 01, 2008
Heel Ultrasound Helps Detect Fracture Risk
Researchers were able to assess which women are at a higher risk of hip fracture by combining the results of a heel ultrasound with known risk factors for osteoporotic fractures…
Monday Jun 30, 2008
Ghrelin, Leptin Changes Link Menstrual Dysfunction, Bone Health in Teen Athletes
Changes in two hormones that affect both appetite and estrogen secretion appear to be the link between athletic activity, loss of menstrual function, and bone health in some adolescent female athletes...
Monday Jun 30, 2008
Preclinical Studies Show that IGF-1-Producing Adult Stem Cells Zoom to Fracture Site, Speed Healing
Preclinical data reported at the 2008 ENDO meeting show that adult stem cell injections might be one approach to treating nonhealing osteoporotic fractures...
Wednesday Jun 25, 2008
Endocrinologists Wrestle With Question of How Long to Continue Bisphosphonate Therapy for Osteoporosis
The jury is still out when it comes to how long bisphosphonate therapy should be continued…
Monday Jun 23, 2008
Lilly, TransPharma Ink Licensing and Development Agreement for Transdermal PTH Program for Osteoporosis
Eli Lilly and TransPharma have entered into a licensing and development agreement for ViaDerm, an agent for the treatment of osteoporosis. Phase II clinical testing of the agent is currently underway...
Monday Jun 23, 2008
More Zoledronic Acid Fracture Reduction Data Reported at Endocrine Society Meeting
Yearly infusions of zoledronic acid 5 mg reduced fractures and increased bone mineral density (BMD) when administered with or without concomitant osteoporosis therapy…
Monday Jun 23, 2008
Hip Fracture Hospitalizations Drop in US Despite Aging Population
New research conducted by a 17-year-old high school student suggests that the US is having a significant impact on the osteoporosis epidemic...
Thursday Jun 19, 2008
Stem Cells Might Treat Tough Fractures
Adult stem cells may be the key to healing broken bones that fail to mend properly on their own…
Tuesday Jun 17, 2008
At 1 Year, Balloon Kyphoplasty Provides Better Pain, Function Outcomes Than Nonsurgical Care for Osteoporotic Vertebral Fractures
After 12 months, patients with acute vertebral compression fractures treated with balloon kyphoplasty had sustained improvements in pain and function compared with those who received nonsurgical care...
Tuesday Jun 10, 2008
Novartis’ Once-Yearly Reclast® Injection 5 mg Receives Revised US Label; Indication to Include Prevention of Fractures After a Hip Fracture
The FDA has broadened the indication for once-yearly Reclast® (zoledronic acid) for postmenopausal osteoporosis to include the prevention of new clinical fractures in patients who have recently had a low-trauma hip fracture...
Thursday Jun 05, 2008
Less Osteoporosis Care, More Hip Fractures Seen in Europe vs Other Countries
European doctors are less likely to screen for or treat osteoporosis, and hip fracture rates in Europe are higher than in North America or Australia, according to baseline data from the ongoing Global Longitudinal registry of Osteoporosis in Women (GLOW)…
Monday Jun 02, 2008
Osteologix Reports Additional Positive Phase II Data for NB S101 (strontium malonate) for Osteoporosis
Osteologix reported that the osteoporosis drug candidate was well-tolerated and significantly suppressed bone resorption while simultaneously improving bone mineral density (BMD) at 12 weeks...
Wednesday May 28, 2008
Wyeth Receives Approval Letter From FDA for Bazedoxifene to Treat Postmenopausal Osteoporosis
The US FDA has issued an approval letter for Wyeth's bazedoxifene, a selective estrogen receptor modulator, for the treatment of postmenopausal osteoporosis...
Tuesday May 27, 2008
More Risedronate Efficacy Data Reported at AACE Meeting
A series of papers reported at the American Association of Clinical Endocrinologists (AACE) 2008 meeting adds to evidence that risedronate (Actonel®) can substantially reduce fracture risk, even when taken only 2 days per month...
Wednesday May 21, 2008
Amgen’s 2nd Phase III Denosumab Osteoporosis Study Meets Primary, Secondary BMD Endpoints in Alendronate Transition Study; Transition Patients Achieved Superior Gains in BMD
Amgen's trial comparing the effects of denosumab vs continued alendronate therapy on bone mineral density demonstrated superior results for primary and all secondary endpoints...
Monday May 19, 2008
AACE Experts Warn of Vitamin D Problems in Vegans, Urge Routine Monitoring in Osteoporosis Patients
Vitamin D deficiency research reported at the 2008 American Association for Clinical Endocrinology meetings included a warning about vegan diets, evidence that osteoporosis patients in treatment are still not getting enough vitamin D, and evidence that even a hip fracture does not lead to adequate vitamin D therapy...
Thursday May 08, 2008
Docs Issue Guideline on Screening for Osteoporosis in Men
New clinical guidelines for screening may combat the expected 50% increase in osteoporosis cases in men…
Friday May 02, 2008
Icelandic and British Researchers ID Five New Osteoporosis Genes
New research spotlighting five genetic loci associated with bone mineral density (BMD) and fractures may provide insight into the biochemical pathways that underlie osteoporosis…
Thursday May 01, 2008
Cola May Be Bad to the Bones
High consumption of soda may contribute to lower bone mass and the eventual development of osteoporosis…
Thursday May 01, 2008
Widely Used Antiepileptic Drug Accelerates Bone Loss in Young Women
Phenytoin, one of the most commonly used antiepileptic drugs (AEDs), causes young women to lose bone mineral density at eight times the normal rate...
Tuesday Apr 29, 2008
Alendronate Linked to Atrial Fibrillation
A case-control study reports that women who have used alendronate are nearly twice as likely to develop atrial fibrillation as those who have never used bisphosphonates...
Friday Apr 25, 2008
FDA Approves New Once-a-Month Dose of Actonel® (risedronate sodium) for Postmenopausal Osteoporosis
The US FDA has approved a new once-a-month dose (150 mg) of Actonel® (risedronate sodium) tablets for the treatment and prevention of postmenopausal osteoporosis...
Monday Apr 21, 2008
Loop Diuretics Pose Osteoporosis Risk for Older Men
Loop diuretics greatly increase hip bone loss in men over age 65...
Friday Apr 18, 2008
Novartis Announces Once-Yearly Reclast Better Than Risedronate at Increasing BMD in GIO Patients; US FDA Approval Sought for Treatment and Prevention of GIO
Novartis Pharmaceuticals Corp reported that a once-yearly infusion of Reclast® (zoledronic acid) injection 5 mg was significantly better than risedronate at increasing BMD in patients with glucocorticoid-induced osteoporosis...
Thursday Apr 17, 2008
Splints as Good as Plaster Casts for Minor Fractures
Removable splits are a safe, effective, and cheaper option than traditional plaster casts for minor wrist fractures in children, but are easily tampered with…
Wednesday Apr 16, 2008
Lilly’s Forsteo® Receives Approval From European Commission for the Treatment of Glucocorticoid-Induced Osteoporosis
Eli Lilly and Co announced that the European Commission has approved a new indication for Forsteo® (teriparatide [rDNA origin] injection) for the treatment of sustained, systemic glucocorticoid-induced osteoporosis (GIOP) in adults at increased risk for fracture...
Tuesday Apr 15, 2008
Novartis Says Aclasta Better at Boosting Bone Mass
Novartis reported study results indicating a once-yearly infusion of Aclasta is more effective than risedronate at increasing bone mass in patients taking steroids...
Thursday Apr 10, 2008
Raloxifene Safe for Women With Decreased Kidney Function
The osteoporosis drug raloxifene is safe for women with CKD, effectively promotes bone density, and reduces fractures…
Tuesday Apr 08, 2008
Testosterone Therapy May Reduce Bone Loss in Older Men
Testosterone injections may improve bone density and prevent osteoporosis in older men with low testosterone levels…
Wednesday Apr 02, 2008
DEXA Scans, Serum Testosterone, Vitamin D Tests Urged for Men Over 70
Osteoporosis in men is a common problem and requires more aggressive diagnosis, treatment, and monitoring of response...
Thursday Mar 20, 2008
Pain Relief for Osteoporosis Patients With Fractures
Vertobroplasty provides significant pain relief for osteoporosis patients with spinal fractures…
Wednesday Mar 19, 2008
LRP5 Gene Variants Linked to Fractures, Lower BMD
Common LRP5 gene variants are associated with an increased risk for fractures and lower levels of bone mineral density (BMD) in the spine and hip across different white populations…
Tuesday Mar 18, 2008
Genzyme Reports That US Data From Large Outcome Studies of Carticel® Support Long-Term Clinical Duration; Prior Marrow Stimulation Techniques May Compromise Treatment With Carticel
Genzyme announced that almost 90% of patients treated with Carticel who experienced improvement in knee function at an early follow-up, sustained their improvement for almost 10 years...
Monday Mar 17, 2008
More Support for WHO's FRAX Fracture Risk Assessment Tool
The International Osteoporosis Foundation hails the use of the new algorithm called FRAX™, which is based on absolute fracture risk and takes bone mineral density (BMD) and 9 specific clinical risk factors into account to estimate a patient's 10-year fracture risk…
Tuesday Mar 11, 2008
Lilly’s Forsteo® Receives Positive Opinion From European Committee for Medicinal Products for Human Use to Treat Glucocorticoid-Induced Osteoporosis
Eli Lilly and Co announced that they have received a positive opinion recommending approval of Forsteo® (teriparatide [rDNA origin] injection) for the treatment of glucocorticoid-induced osteoporosis (GIOP) in adults at increased risk for fracture...
Tuesday Mar 11, 2008
AAOS Researchers Warn of Alendronate Fracture Risk
Two studies reported at the AAOS meeting warned of a possible increase in risk of low-energy or stress fractures associated with long-term use of alendronate...
Monday Mar 10, 2008
AAOS Panel Presents Hip Resurfacing as Option for Some Younger Patients
Hip resurfacing may emerge as a preferred option for some younger arthritis patients...
Friday Mar 07, 2008
Sports Doctors Urge for More Injury Prevention in Women Athletes
Sex matters in sports injuries, and more attention to special problems of women athletes is needed...
Tuesday Mar 04, 2008
P&G Wins Patent Infringement Lawsuit for Osteoporosis Therapy Actonel®; Teva to Appeal Court Ruling
Procter & Gamble announced that the US District Court of Delaware ruled in its favor in the patent infringement lawsuit the company filed against Teva Pharmaceuticals USA, Inc...
Thursday Feb 28, 2008
Acceleron, Celgene to Collaborate on Anabolic Bone Agent ACE-011, a Decoy Activin Receptor, for Cancer-Related Bone Loss
Acceleron Pharma and Celgene Corp announced a worldwide strategic collaboration for the development and commercialization of ACE-011, a novel bone-forming compound for the treatment of cancer-related bone loss...
Monday Feb 25, 2008
New Guide Helps Predict 10-Year Fracture Risk
A new guide can help doctors evaluate fracture risk and make treatment decisions in patients with osteopenia and osteoporosis...
Tuesday Feb 05, 2008
Inverse Relationship Between Vertebral Fractures and Spine Osteoarthritis in Postmenopausal Women With Osteoporosis
Disc space narrowing decreases the incidence of vertebral fracture in postmenopausal women with osteoporosis...
Monday Feb 04, 2008
Cochrane Review: Alendronate Safe, Effective for Secondary Fracture Prevention
Alendronate can stave off vertebral, nonvertebral, hip, and wrist fractures among postmenopausal women with low bone density and/or those with previous fractures...
Tuesday Jan 29, 2008
Adding Vitamin D Reduces Risk of Falls in High-Risk Elderly Women
Community-dwelling elderly women with a history of falling and vitamin D deficiency have a 19% reduction in falls when supplementary vitamin D is added to calcium, even if they live in sunny areas...
Monday Jan 28, 2008
Amgen Reports Denosumab Osteoporosis Study Met Primary and All Secondary BMD Endpoints in a Direct Comparison With Weekly Alendronate (Fosamax®)
Amgen Inc announced findings from a head-to-head, double-blind study comparing the effects of twice-yearly subcutaneous injections of denosumab versus weekly oral doses of alendronate in postmenopausal women with low bone mineral density...
Friday Jan 25, 2008
Do Calcium Supplements Help Bones at the Expense of the Heart?
Calcium supplements may increase the risk of heart attack and stroke in healthy postmenopausal women...
Friday Jan 25, 2008
Low Serum Testosterone Predicts Fracture Risk in Older Men
Men with serum testosterone <294 ng/dL have a significantly increased risk of nontraumatic fracture and should be referred for bone density assessment...
Friday Jan 18, 2008
Bone Experts Slam New UK Limits on Osteoporosis Drugs
Some of the biggest names in osteoporosis have signed on to two papers in Bone that criticize the latest UK National Institute for Health and Clinical Excellence (NICE) recommendations on drugs for prevention of osteoporotic fractures, in essence charging that the agency gamed its analysis to cut costs for the National Health Service...
Thursday Jan 17, 2008
Incidental Vertebral Fractures on Multidetector CT Images of the Chest: Prevalence and Recognition
Vertebral fractures are under diagnosed by radiologists using multidetector computed tomography...
Thursday Dec 20, 2007
OARSI Researchers Further Refine Matrix-Associated Cartilage Repair Techniques
Matrix-associated autologous chondrocyte implantation continues to improve as a way of repairing arthritis knees, and MRI can be used to check the quality of the repaired tissue...
Thursday Dec 20, 2007
New EULAR Recommendations on Systemic Glucocorticoids Stress Monitoring for Adverse Events
EULAR has issued new evidence-based recommendations on the management of systemic glucocorticoid therapy in rheumatic diseases...
Tuesday Dec 18, 2007
Amgen's Pivotal Phase III Data Show Denosumab With Twice-Yearly Dosing Increased BMD Throughout Skeleton in Nonmetastatic Breast Cancer Patients on Adjuvant Aromatase Inhibitor Therapy; Study Met All Primary and Secondary Endpoints
Amgen Inc announced that pivotal phase III data show that denosumab, a fully human monoclonal antibody that specifically targets the receptor activator of nuclear factor kappa B ligand, a key mediator of the resorptive phase of bone remodeling, increased bone mineral density throughout the skeleton in nonmetastatic breast cancer patients on adjuvant aromatase inhibitor therapy...
Monday Dec 10, 2007
Doctors Rally to Save DXA from Medicare Cuts
If proposed Medicare cuts that would drastically reduce access to dual X-ray absorptiometry (DXA) are approved, many physicians will be unable able to offer DXA services in their offices and undetected osteoporotic fracture rates are likely to climb, healthcare researchers predict...
Thursday Dec 06, 2007
IM Vitamin D Provides Little Fracture Protection in Relatively Healthy, Community-Dwelling Elderly
If fracture risk in the elderly is associated with low vitamin D levels, why doesn't an annual vitamin D injection reduce fracture rates?...
Friday Nov 30, 2007
Osteoporosis Also Contributes to High-Trauma Fractures
Thursday Nov 29, 2007
New Method Provides Quick Estimate of 5-Year Hip Fracture Risk
A new algorithm based on 11 clinical factors can predict 5-year risk for hip fracture in postmenopausal women...
Thursday Nov 29, 2007
Osteoporosis Also Contributes to High-Trauma Fractures
Physicians should evaluate older patients with high-trauma nonspine fractures for osteoporosis...
Monday Nov 26, 2007
Teriparatide Builds More Bone Than Alendronate in Steroid-Caused Osteoporosis
Teriparatide built more bone mass and prevented more vertebral fractures than alendronate in the first head-to-head study of the two drugs for glucocorticoid-induced osteoporosis...
Friday Nov 02, 2007
Strontium Ranelate May Slow Osteoarthritis Progression
The osteoporosis drug strontium ranelate (Protelos®) may stop or slow the progression of osteoarthritis (OA) and also might alleviate back pain...
Thursday Oct 25, 2007
Prostate Cancer Doubles Fracture Risk
Men with prostate cancer treated with orchidectomy or androgen deprivation are at increased risk for fractures, particularly of the hip, and should have bone density evaluated regularly...
Monday Oct 15, 2007
Enlarging Bone Marrow Lesions Add to Knee Pain
Research shows that new onset knee pain was strongly linked with an increase of two or more units in bone marrow lesions...
Friday Oct 12, 2007
Novartis' Aclasta® Receives EU Approval as First Once-Yearly Treatment for Postmenopausal Osteoporosis
Novartis Pharmaceuticals AG announced that Aclasta® (zoledronic acid 5 mg) has received EU approval as the first once-yearly treatment for women with postmenopausal osteoporosis...
Thursday Oct 04, 2007
Celera Receives Clinical Milestone Payment Based on Merck's Advancement of Odanacatib, a Cathepsin K Inhibitor; Phase III Trial for Osteoporosis Initiated
Celera, an Applera Corp business, announced a clinical milestone payment of $2 million from Merck & Co, Inc, under the cathepsin K inhibitor collaboration agreement between the companies...
Friday Sep 28, 2007
Surprise Data From ASBMR: Keep Antiresorptive Going When Adding Teriparatide
A randomized trial testing whether osteoporosis patients on long-term antiresorptive treatment benefit more from switching to teriparatide or from adding the new drug shows conclusively that it is better to add than to switch...
Thursday Sep 20, 2007
Vitamin D + Calcium Decrease Risk of Falling; Vitamin K1 Effect Not Due to Improved BMD
Researchers at the ASBRM report that vitamin D and calcium decrease the risk of falling in postmenopausal women and that the protective effect of vitamin K1 is not due to improving BMD...Kärkkäinen M, et al; Cheung AM, et al. ASBMR 2007.
Monday Sep 17, 2007
Once-Yearly Zoledronate Cuts Mortality After Hip Fracture by 28%
A single yearly dose of zoledronic acid can significantly reduce the risk of second fracture and decrease mortality in older patients who have had a hip fracture...Lyles KW, et al. ASBMR 2007.
Thursday Sep 13, 2007
Hormone Therapy Does Not Worsen Lupus But May Increase Thrombosis Risk
Menopause hormonal therapy does not worsen lupus disease activity or trigger disease flares but may add to an already high risk of thrombosis in women with SLE...
Wednesday Sep 05, 2007
Health Canada Approves Actonel® 75 mg; First 2-Day Monthly Dosing Regimen to Treat Postmenopausal Osteoporosis
The Alliance for Better Bone Health, formed in 1997 by Procter & Gamble and Aventis Pharmaceuticals Inc (now part of sanofi-aventis) to promote bone health and disease awareness, announced that the government's Health Canada has approved Actonel® (risedronate sodium tablets) 75 mg, the first monthly 2-day dosing regimen for the treatment of postmenopausal osteoporosis...
Thursday Aug 30, 2007
Vitamin K2 Supplements Protect Bone Architecture
Three years of dietary supplementation with vitamin K2 maintained bone strength and architecture despite having little effect on BMD...
Tuesday Aug 28, 2007
Interleukin Genetics Collaborates With NYU Medical Center to Evaluate Genetic Patterns Associated With IL-1β Overproduction and Development of Polyarticular OA
Interleukin Genetics, a genetics-focused personalized health company, announced today that it has initiated a study on the genetics of osteoarthritis (OA) in collaboration with the Hospital for Joint Diseases of New York University Medical Center...
Monday Aug 27, 2007
Harkness Dance Medicine Head Urges Clinicians to Prepare for the "High School Musical 2" Generation
Musicals are back, dance classes are filled, clinicians are facing more dancers or former dancers with musculoskeletal problems, and dance medicine experts are urging clinicians to heed the beat of dancing feet...
Monday Aug 20, 2007
Novartis' Once-Yearly Reclast® Receives US FDA Approval for Women With Postmenopausal Osteoporosis
Novartis Pharmaceuticals Corp announced that its once-yearly, 15-minute infusion treatment of Reclast® (zoledronic acid) injection has been approved by the US FDA for women with postmenopausal osteoporosis...
Thursday Aug 09, 2007
Osteoporosis Screening, Treatment Recommended for Older Men Only if History of Fracture or Over Age 80
Osteoporosis screening of all men over age 70 plus bisphosphonates for those with osteoporosis is not a cost-effective strategy for fracture prevention at current drug cost levels but might be reasonable for men 65 or older with prior fracture and for men 80 or older even without prior fracture...Schousboe JT, et al. JAMA. 2007;298:629-637.
Thursday Aug 09, 2007
Does Collagen Stimulate Its Own Degradation in OA Joints?
Chondrocytes are exposed to collagen in OA cartilage but not in normal joints. This process appears to trigger DDR-2-mediated expression of enzymes that further degrade collagen and add to joint destruction...Xu L et al, and Sandell LJ. Arthritis Rheum. 2007;2663-2673 and 2474-2477.
Thursday Aug 02, 2007
Stem Cell Transplants Offer Hope for Children With Severe, Refractory JIA
Intensive immunosuppression followed by T-cell-depleted autologous hematopoietic stem cell transplantation offers refractory JIA patients a chance for remission, but is it worth the risks?…Brinkman DMC, et al. Arthritis Rheum. 2007;56:2410-2421.
Thursday Jul 26, 2007
Vitamin C After Wrist Fracture Prevents Chronic Pain Syndrome
Vitamin C (500 mg/day) taken for 50 days after wrist fracture significantly reduces the risk of developing complex regional pain syndrome...
Wednesday Jul 25, 2007
Hip Protectors Fail to Prevent Hip Fracture in Nursing Home Residents
Energy-absorbing/shunting hip protectors do not protect nursing home residents from hip fractures…Kiel DP, et al. JAMA. 2007;298:413-422.
Tuesday Jul 24, 2007
Novartis Receives Positive Opinion Supporting EU Approval for Aclasta® as the First Once-Yearly Treatment for Women With Postmenopausal Osteoporosis
Novartis Pharmaceuticals AG announced that it has been informed by the European Medicines Agency that the Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion on the marketing application for the use of Aclasta®.
Thursday Jul 05, 2007
Too Much Early, Aggressive Care Slows Recovery From Whiplash
Early, aggressive treatment of whiplash impedes recovery, and adding chiropractic to general medical care slows recuperation even more...
Thursday Jun 28, 2007
FDA Approves New Labeling for Carticel® in Repair of Articular Knee Cartilage
Genzyme Corporation announced that the US FDA has approved new labeling for Carticel® based on the company's completing a final FDA postapproval commitment study...
Thursday Jun 28, 2007
Zoledronate Reduces Bone Turnover, Preserves Bone Quality
Once-yearly zoledronate infusion both reduces bone turnover and preserves trabecular bone structure…
Monday Jun 11, 2007
Centocor's Remicade® (Infliximab) Receives EU Approval as First and Only Biologic for the Treatment of Pediatric Patients With Severe, Active Crohn's Disease
Centocor, Inc, a wholly owned subsidiary of Johnson & Johnson and Schering-Plough Corp, announced that the European Commission has approved a new indication for Remicade (infliximab) allowing for the treatment of severe, active Crohn's disease (CD) in pediatric patients ages 6 to 17 years, who have not responded to conventional therapy including a corticosteroid, an immunomodulator, and primary nutrition therapy, or who are intolerant to, or have contraindications for such therapies...
Thursday Jun 07, 2007
High Plasma Homocysteine Predicts Hip Fracture
Elevated plasma total homocysteine (tHcy) may be a modifiable risk factor for osteoporotic hip fracture...
Monday Jun 04, 2007
Is Resistance Exercise the Fountain of Youth?
Resistance training may help reverse aging in skeletal muscle by altering mitochondrial function among healthy seniors...
Monday May 21, 2007
Risedronate Bests Alendronate for Fracture Reduction in REAL-World Setting
Patients receiving once-weekly risedronate have lower rates of hip and nonvertebral fractures during their first year of therapy than their counterparts who receive once-weekly alendronate...
Tuesday May 08, 2007
2-Year Results Support Use of New Chondrocyte Graft to Repair Knee OA Damage
Two-year follow-up of a new 3-dimensional scaffold that permits grafting of autologous chondrocyte to repair knee cartilage defects show promising results in both knee OA and knee trauma, and the procedure can be done arthroscopically...
Monday May 07, 2007
Novartis' Once-Yearly ReclastR Significantly Reduces Bone Fractures in Women With Postmenopausal Osteoporosis
Novartis Pharmaceuticals Corp announced that its once-yearly treatment of ReclastR (zoledronic acid) significantly reduces the incidence of all types of osteoporotic bone fractures in women with postmenopausal osteoporosis...
Wednesday May 02, 2007
Yearly Injection of Zoledronic Acid Cuts Spine Fracture Risk by 70%
A single intravenous 5-mg dose of zoledronic acid (Reclast®), given once yearly, can significantly reduce the risk of vertebral, hip,and other fractures, but its major advantage may lie in the ease of administration…
Friday Apr 27, 2007
Wyeth Receives Approvable Letter from FDA for Bazedoxifene for the Prevention of Postmenopausal Osteoporosis
Wyeth Pharmaceuticals, a division of Wyeth, announced that the US FDA has issued an approvable letter for bazedoxifene (ViviantTM), a selective estrogen receptor modulator (SERM) for the prevention of postmenopausal osteoporosis...
Thursday Apr 26, 2007
Balance Training May Help Reverse Frailty, Prevent Osteoporosis-Related Fractures
Balance training alone or in combination with strength, agility and jumping training can reduce the risk of falls and prevent frailty in women at risk of osteoporosis…
Tuesday Mar 27, 2007
Osteoporosis Fractures, Costs Expected to Jump 50% by 2025
Hispanics likely to experience increases in fractures and their costs. Pelvic fractures and associated costs are expected to double by 2025…
Wednesday Mar 21, 2007
BioMimetic Receives Orphan Drug Designation for rhPDGF-BB Treatment of Osteonecrosis of the Jaw
BioMimetic Therapeutics, Inc, an emerging leader in developing and commercializing bioactive drug-device combination drugs to heal musculoskeletal injuries and disease, including periodontal, orthopaedic, spine and sports injuries, announced that it has received orphan drug designation from the US FDA for its protein therapeutic, recombinant human platelet-derived growth factor (rhPDGF-BB)...
Monday Mar 12, 2007
Novartis, Nordic Bioscience to Initiate Osteoporosis Phase III Program Using Emisphere's EligenR Technology for Oral Salmon Calcitonin
Emisphere Technologies, Inc, a biopharmaceutical company pioneering the oral delivery of otherwise injectable drugs, announces that Novartis Pharmaceutical AG and its development partner Nordic Bioscience A/S will initiate a phase III clinical trial for the treatment of osteoporosis with an oral form of salmon calcitonin (SMC021), a new drug candidate, using Emisphere's eligen® delivery technology...
Tuesday Mar 06, 2007
Coxibs and Other NSAIDs Delay Fracture Healing If Used At Wrong Time
Use of COX-2 inhibitors to deaden pain in the 14 days after a fracture might also inhibit fracture healing, although use of the drugs prior to or more than 2 weeks after injury seems safe...
Tuesday Feb 27, 2007
GSK Reports Clinical Trial Observation of an Increased Incidence of Fractures in Female Patients Who Received Long-Term Treatment with Avandia (rosiglitazone maleate) Tablets for Type 2 Diabetes Mellitus
GlaxoSmithKline (GSK) informs healthcare providers of recent safety data concerning rosiglitazone-containing products, ie, Avandia® (rosiglitazone maleate) tablets, AvandametR (rosiglitazone maleate and metformin hydrochloride) tablets, and Avandarylâ„¢ (rosiglitazone maleate and glimepiride) tablets...
Thursday Feb 15, 2007
Experts at the 74th Annual Meeting of the American Academy of Orthopaedic Surgeons Predict Clinically Useful Gene Therapy, Tissue Engineering Will Be Available "in 5 to 10 Years"
Presentations at the AAOS meeting include advances in both gene therapy and tissue-engineered products for cartilage, bone, and tendon repair...
Thursday Jan 25, 2007
Questions Raised About Study That Links SSRIs to Doubling of Fracture Risk in Elderly
A cohort study of minimal trauma fractures in community-dwelling elderly patients recently concluded that daily use of SSRI antidepressants doubles fracture risk, but the data may not be strong enough to justify that conclusion...
Tuesday Jan 23, 2007
Older Men Are as Vulnerable to Second Osteoporotic Fractures as Women—and Receive Even Less Treatment
After a first low-trauma fracture, men are as likely as women to have a second fracture and are less likely to receive osteoporosis care...
Wednesday Jan 17, 2007
Rheumatologists May Be Doing Better at Treating Osteoporosis in RA Patients
Management of osteoporosis in rheumatoid arthritis (RA) patients has improved modestly since 1999 (at least in one large academic practice)...
Wednesday Jan 17, 2007
Genzyme's Cerezyme Improves Bone Mineral Density in Patients With Type 1 Gaucher Disease
Genzyme Corporation (CAMBRIDGE, Massachusetts) announced that long-term use of Cerezyme® (imiglucerase for injection) significantly improves bone mineral density (BMD) in patients with Type 1 Gaucher disease in a dose-dependent manner. Cerezyme, an enzyme replacement therapy, is the standard of care for patients with Type 1 Gaucher disease who are at increased risk for developing bone complications, including osteopenia, osteoporosis, and fractures...
Thursday Jan 11, 2007
New Study Challenges Role of Low Vitamin D in OA Worsening
Low vitamin D levels did not predict worsening of knee OA joint space narrowing or cartilage loss...
Thursday Dec 07, 2006
Osteologix Initiates Phase II Clinical Trial of Strontium Malonate (NB S101) for Osteoporosis
Osteologix Inc, a developer of proprietary therapeutics for the treatment of bone disease and women's health, announced that it has initiated a randomized, double-blind, placebo-controlled, phase II dose-response study in healthy postmenopausal women of its lead investigational drug, strontium malonate (NB S101) for osteoporosis.
Tuesday Dec 05, 2006
Nastech, P&G Amend Agreement for Development of Parathyroid Hormone (PTH1-34) Nasal Spray for Treatment of Osteoporosis
Nastech Pharmaceutical Company Inc (BOTHELL, Washington) announced the amendment of its previous agreement with Procter & Gamble Pharmaceuticals, Inc (P&G) for the clinical development program of the parathyroid hormone (PTH1-34) nasal spray for the treatment of osteoporosis. The amendment includes an additional phase II dose ranging study as well as a change in the timing of payments.
Thursday Nov 30, 2006
Low Risk of Jaw Osteonecrosis Seen With Bisphosphonates for Osteoporosis
Osteonecrosis of the jaw has emerged as an unanticipated problem associated with bisphosphonate treatment in cancer patients, but is seldom a significant risk at the doses used for osteoporosis...
Tuesday Nov 21, 2006
Study Helps Explain Why Smoking Slows Ligament and Bone Healing
Smoking cigarettes delays cartilage formation in healing bone fractures and slows type I collagen production and recruitment of cells linked to healing of torn ligaments…
Wednesday Nov 15, 2006
Once-Yearly Zoledronic Acid Injection Reduces Fracture Risk, Improves Bone Structure in Postmenopausal Women With Osteoporosis
Once-yearly injections of zoledronic acid 5 mg reduces fracture risk, improves bone mineral density, and improves bone structure in women with osteoporosis... Black DM, Recker RR. Presented at ACR 2006 Meeting.
Wednesday Oct 25, 2006
Fracture Risk Higher in RA Patients
RA patients are at an increased risk of osteoporotic fractures due to a combination of disease activity, low BMI, and oral glucocorticoid use... van Staa, TP, et al. Arthritis Rheum. 2006;54:3104–3112.
Monday Oct 16, 2006
Potassium Citrate Supplements Increase Bone Mass
Potassium citrate supplements might help postmenopausal women with osteopenia increase their bone mineral density (BMD)... Jehle S, et al. J Am Soc Nephrol. 2006;17:3213–3222.
Tuesday Oct 03, 2006
FRISK Score Seen As Alternative to T- or Z-Score for Predicting Fracture Risk
The Fracture Risk (FRISK) Score was developed to predict fracture more accurately than bone mineral density alone, but questions have been raised about its clinical usefulness... Henry MJ, et al. Radiology. 2006:241:190-196.
Monday Sep 18, 2006
Novartis' Once-Yearly Reclast Investigational Infusion Osteoporosis Treatment Significantly Cuts Risk of Spine and Hip Fractures in Postmenopausal Women
Novartis Pharmaceuticals Corporation announced that phase III data presented at the 28th Annual meeting of the American Society for Bone and Mineral Research (ASBMR), September 15–19, 2006, in Philadelphia, Pa, demonstrated that its investigational, once-yearly bisphosphonate 15-minute infusion treatment, Reclast® (zoledronic acid) 5 mg, was highly effective at reducing the incidence of bone fracture in women with postmenopausal osteoporosis across the most common fracture sites—hip, spine, and nonspine (with the exception of face, fingers, and toes)—with sustained effect over 3 years.
Thursday Aug 31, 2006
Alendronate Better Than Alfacalcidol for Preventing GC-Induced Bone Loss
A randomized, double-blind clinical trial finds that alendronate is significantly better than alfacalcidol at preventing glucocorticoid-induced bone loss and reducing fracture risk...
Thursday Aug 31, 2006
COX-2 Inhibitors Decrease Bone Density in Men, Improve It in Some Women
COX-2 inhibitors decrease bone density in men but increase it in postmenopausal women not taking estrogen, confirming the role of inflammation in postmenopausal bone loss... Richards JB, et al. Osteoporosis Int. 2006;17:1410-1419.
Monday Aug 14, 2006
TissueGene Initiates Phase I Study of TissueGene-C in Patients With Degenerative Joint Disease of the Knee Prior to Total Knee Arthroplasty
TissueGene, Inc. announced the initiation of a phase I clinical trial of the company's cell-mediated therapy, TissueGene-C (TG-C).
Wednesday Aug 09, 2006
TransPharma Medical Raises $18 Million to Advance Clinical Development of Transdermal hPTH (1-34) for Osteoporosis
TransPharma Medical Ltd, has raised $18 million in a Series C round of financing, led by Argonaut Private Equity and including an additional new investor, Teva Pharmaceutical Industries Ltd, as well as TransPharma's current investors.
Tuesday Aug 08, 2006
Geron and University of Edinburgh to Collaborate in Conducting Preclinical Studies with Cell Types Derived from Human Embryonic Stem Cells for Musculoskeletal Applications
Geron Corporation and the University of Edinburgh announced that they have entered into a collaboration to conduct preclinical safety and efficacy studies with three cell types derived from human embryonic stem cells.
Monday Jul 31, 2006
Steroids Cause Osteoporosis by Blocking Osteoclast Role in Bone Remodeling
The bone loss caused by glucocortocoid treatment is due to steroid-induced changes in osteoclasts, which then fail to create the conditions osteoblasts need to accomplish new bone formation....Kim H-J, et al. J Clin Invest. 2006 July 27 [Epub ahead of print].
Friday Jul 28, 2006
Strontium Ranelate Reduces Fracture Risk in Postmenopausal Women With Osteoporosis
Strontium ranelate significantly reduces the risk of veretebral fractures, increases BMD at all sites and may prevent nonspine fracture in postmenopausal women with osteoporosis, a Cochrane Review concludes. ... O'Donnell S, et al. Cochrane Database for Systematic Reviews. 2006, Issue 3.
Friday Jun 23, 2006
Kyphoplasty Reduces Osteoporotic Fracture Pain, but Does It Predispose to More Fractures?
Pharmacologic treatments for osteoporosis leave up to 50% of patients suffering long-term pain from fractures—perhaps unnecessarily... Kasperk C. Presented at: EULAR 2006; June 21–24, 2006; Amsterdam, The Netherlands. Abstract SP0033.
Tuesday Jun 20, 2006
Nastech Receives $7 Million Milestone Payment From P&G; Will Make and Supply to P&G PTH1-34 Nasal Spray for Osteoporosis
Nastech Pharmaceutical Company Inc, of Bothell, Washington, announced the receipt of a $7 million payment for attaining a development milestone under its development and commercialization agreement with Procter & Gamble Pharmaceuticals, Inc, pertaining to parathyroid hormone (PTH1-34) nasal spray for the treatment of osteoporosis...
Tuesday Jun 20, 2006
Crescent Diagnostics Raises US$1 Million to Advance the Development of its Novel Bone Quality Testâ„¢ as a Surrogate Marker for Bone Structure
Crescent Diagnostics Ltd, of London, UK, and Limerick, Ireland, announced the completion of a US$1 million funding round led by Seroba BioVentures, a Dublin-based specialist life science venture capital firm...
Thursday Jun 15, 2006
Alendronate More Cost-Effective Than Teriparatide
Teriparatide could become cost-effective if its price were reduced by 60 percent, if it were given only to women with exceptionally low bone density, or if a 6-month course of teriparatide were as effective in preventing fractures at 2 years of treatment... Liu H, et al. Arch Intern Med. 2006;166:1209-1217.
Tuesday May 30, 2006
Give Bisphosphonates and Teriparatide Sequentially, Not Together
Alendronate reduces the ability of once-daily teriparatide to stimulate new bone formation in osteoporotic men; the two drugs therefore should not be given concurrently... Finkelstein JS, et al. J Clin Endocrinol Metab. 9 May 2006; [Epub ahead of print]
Wednesday May 24, 2006
Bone-Sparing, Metal-on-Metal Hip Resurfacing System Benefits Young, Active Patients
A just-approved bone-sparing hip-resurfacing system will likely relieve pain and improve hip function among younger, active patients who have good bone quality, but caveats remain...
Monday May 22, 2006
Second Year of FACT Trial Confirms Alendronate Advantage Over Risedronate for Preventing Bone Loss
Twenty-four-month data show that alendronate surpasses risedronate in reducing the risk of bone loss in postmenopausal women with osteoporosis... Bonnick S, et al. Clin Endocrin Metab. 24 April 2006; [Epub ahead of print]
Tuesday May 09, 2006
Calcium Supplements Don't Reduce Fracture Risk Unless Patients Take Them
Supplementation with calcium carbonate tablets is ineffective at reducing fracture rates in the ambulatory elderly as a mass public health intervention due to poor long-term compliance, but the supplements are effective in patients who actually take them... Prince RL, et al. Arch Intern Med. 2006;166:869-875.
Monday May 01, 2006
Nastech's Intranasal Parathyroid Hormone (PTH1-34) Demonstrates Similar Pharmacokinetic Profile to Approved Injectable Product, ForteoR (Teriparatide)
Nastech Pharmaceutical Company Inc, of Bothell, Washington, reported pharmacokinetic data from a phase I study of parathyroid hormone (PTH1-34) nasal spray demonstrating a similar pharmacokinetic profile to the approved subcutaneous product, Forteo®...
Thursday Apr 06, 2006
BMP-6 is a Potent Inducer of Chondrogenesis in Adipose-Derived Adult Stem Cells
Bone morphogenetic protein 6 (BMP-6) stimulates the differentiation of human adipose-derived adult stem (ADAS) cells into cartilage cells... Estes BT, et al. Arthritis Rheum. 2006;54:1222-1232.
Monday Mar 20, 2006
Single Injection of GDF-5 May Repair Degenerated Discs
A single injection of recombinant human growth and differentiation factor (GDF-5) may induce recovery of intravertebral disc height... Presented at: 52nd Annual Meeting of the Orthopaedic Research Society; March 18–22, 2006; Chicago, Ill. Abstract 14.
Monday Mar 13, 2006
NPS Receives Approvable Letter From US FDA for Recombinant Human Parathyroid Hormone for Osteoporosis; FDA Expresses Concern Regarding Hypercalcemia
NPS Pharmaceuticals, Inc, of Salt Lake City, Utah, announced that it has received an "approvable letter" from the US Food and Drug Administration (FDA) for their new drug application for PREOS®...
Thursday Mar 02, 2006
Denosumab Shows Promise in Phase II Study of Bone Mineral Density
Twice yearly injections of denosumab (previously known as AMG 162) significantly increased bone mineral density in the total hip, lumbar spine, distal 1/3 radius, and total body of postmenopausal women compared with placebo... McClung MR, et al. N Engl J Med. 2006;354:821-831.
Thursday Mar 02, 2006
Simple Formula Helps Doctors Determine When Height Loss Signifies Osteoporosis
Historical height loss can help predict the likelihood of vertebral fractures and the need for spine radiographs... Siminoski K, et al. Osteoporos Int. 2006;17:290-296.
Friday Feb 17, 2006
Calcium With Vitamin D Does Not Decrease Risk of Hip Fracture in Postmenopausal Women
Calcium with vitamin D does not decrease risk of hip fracture and only shows a modest benefit in bone density... Jackson RD, et al. New Engl J Med. 2006;354:669-683.
Monday Feb 13, 2006
BioMimetic Therapeutics Files for IPO
BioMimetic Therapeutics, Inc, of Franklin, Tennessee, announced that it has filed a registration statement with the US Securities and Exchange Commission...
Thursday Jan 26, 2006
Risk of New Fractures Found to Increase After Vertebroplasty
A nonsurgical therapy used to heal vertebral compression fractures, vertebroplasty may increase the risk of new fractures in adjacent vertebrae... Trout AT, et al. Am J Neuroradiol. 2006;27:217-223.
Friday Jan 20, 2006
Patients with Chronic Skin Disease Who Require Long-Term Corticosteroids Not Receiving Bisphosphonates
Most patients who receive prolonged oral corticosteroids for chronic skin diseases such as pemphigus vulgaris and cutaneous lupus erythematosus are not receiving bisphosphonates... Liu RH, et al. Arch Dermatol. 2006;142:37-41.
Wednesday Jan 18, 2006
P&G and Sanofi-Aventis File Lawsuit Against Roche and GSK Alleging False and Misleading Advertising for Osteoporosis Drug Boniva®
Procter & Gamble Pharmaceuticals and Sanofi-Aventis US, LLC, co-marketers of Actonel® (risedronate sodium) tablets, announced that they have filed...
Tuesday Jan 10, 2006
Federal Court Rules Lilly Breached Agreement with Emisphere Regarding Oral Formulation of Forteo® for Osteoporosis; Lilly turns to Alkermes for Development of Inhaled Version
Emisphere Technologies, Inc, of Tarrytown, NY, announced that a Federal District Court judge ruled that Eli Lilly and Company had violated an agreement with Emisphere regarding the use of Emisphere's Eligen technology for the development of an oral formulation of Forteo® ...
Wednesday Dec 21, 2005
EMG May Be Better Than MRI at Diagnosing Spinal Stenosis
Because it can test nerve function and determine the presence of nerve damage, electromyogram testing may be more effective than magnetic resonance imaging in diagnosing spinal stenosis as well as detecting neuromuscular diseases that mimic stenosis... Haig AJ, et al. Spine. In press.
Friday Dec 02, 2005
New Study Indicates Fear of Addiction Among Other Surprising Reasons for Poor Adherence to Bisphosphonate Therapy
While lack of adherence to bisphosphonates is well-known, recent research has shed new light on possible causes, including difficulties in following prescribing instructions, frequency of dosing schedules, potential drug-drug interactions, and fear of addiction… Presented at: Annual Meeting of the American College of Rheumatology; San Diego, Calif. Abstract 625.
Wednesday Oct 12, 2005
Nastech Reports Positive Phase I Data for Intranasal PTH 1-34 for Osteoporosis
Nastech Pharmaceutical Company Inc, of Bothell, Washington, a leader in molecular biology-based drug delivery technologies, announced...
Thursday Oct 06, 2005
New Study Results Suggest That Two Courses of Parathyroid Hormone May Reduce Fracture Risk in Patients with Severe Osteoporosis
Osteoporosis patients who remain at high risk for fracture despite a course of parathyroid hormone (PTH) therapy may benefit from a second discrete course of PTH . . . Presented at: 27th Annual Meeting of the American Society for Bone and Mineral Research; September 23–27, 2005; Nashville, Tenn. Presentation 1079.
Wednesday Oct 05, 2005
New Bone Biopsy Data Support Safety of Dual-Acting Strontium Ranelate for Osteoporosis
A potentially dual-acting new osteoporosis medication, strontium ranelate, may safely decrease bone resorption while increasing bone formation, rebalancing bone turnover toward formation . . . Presented at: 27th Annual Meeting of the American Society for Bone and Mineral Research; September 23–27, 2005; Nashville, Tenn. Abstract 1084.
Monday Oct 03, 2005
Osteologix's Low-Dose Strontium-Based Compound Shows Bioequivalence to Strontium Ranelate in Phase I Trial
Osteologix, Inc, headquartered in San Francisco, California, announced that its phase I clinical trial of NBS-101...
Monday Oct 03, 2005
Acologix's AC-100 Shows Positive Preclinical Activity for Bone and Dental Applications
Acologix, Inc, of Hayward, California, a privately held biopharmaceutical company targeting bone and kidney diseases, presented preclinical data...
Friday Sep 30, 2005
Childhood Fractures May Be a Risk Factor for Osteoporosis
A new study suggests that a history of fracture in childhood and adolescence may be a marker for genetically determined low peak bone mass and osteoporosis later in life... Presented at: 27th Annual Meeting of the American Society for Bone and Mineral Research; September 23-27, 2005; Nashville, Tenn. Abstract 1136.
Thursday Sep 29, 2005
Study Suggests Statins May Lower Fracture Risk in Men
A study of almost 30,000 elderly men suggests that statins, in addition to their lipid-lowering benefit, may also reduce fracture risk...Scranton RE, et al. Arch Intern Med. 2005;165:2007-2012.
Thursday Sep 29, 2005
Long-Term Bisphosphonate Therapy Remains an Unresolved Issue
Despite concerns about long-term bisphosphonate therapy resulting in the continued suppression of bone turnover and inhibition of normal repair and replacement of damaged bone, recent clinical trials suggest that treatment for up to 10 years is not harmful ... Presented at: 27th Annual Meeting of the American Society for Bone and Mineral Research; September 23-25, 2005; Nashville, Tenn.
Wednesday Sep 28, 2005
The XtremeCT May Be More Sensitive than DEXA in Predicting Fracture Risks
A new high-resolution imaging device, the XtremeCT, which measures both bone density and bone architecture, may have significant advantages over the current gold standard, dual-energy x-ray absorptiometry (DEXA)...Boutroy S, et al. Presented at: 27th Annual Meeting of the American Society for Bone and Mineral Research; September 23-27, 2005; Nashville, Tenn. Abstract SA360.
Tuesday Sep 27, 2005
Novel Method of Upfront Loading of Bisphosphonates Found to Improve Spinal Bone Mineral Density and Reduce Fractures
Upfront loading of oral or intravenous bisphosphonates followed by maintenance dosing may enhance the ability of these agents to reduce fracture risk compared with currently used dosing regimens... Presented at: 27th Annual Meeting of the American Society for Bone and Mineral Research; September 23-27, 2005; Nashville, Tennessee. Abstract M369.
Tuesday Sep 27, 2005
Mesoblast Limited to Start Human Orthopaedic Trial Using Adult Stem Cell Technology
Mesoblast Limited of Melbourne, Australia, a biotechnology company that develops adult mesenchymal precursor stem cell technology for the regeneration and repair of bone and cartilage, has announced...
Tuesday Sep 27, 2005
Competitive Technologies Licenses Bone Biomaterial to Soteira for Spinal Applications
Competitive Technologies, Inc (CTT), a technology transfer and licensing provider, has granted Soteira, Inc, of Dedham, Massachusetts...
Tuesday Sep 27, 2005
Researchers Report Promising Findings on Biomarkers for Postmenopausal Osteoporosis and OA
New research has uncovered biomarkers that serve as both diagnostic "fingerprints" for the risk of postmenopausal osteoporosis and predictors for osteoarthritis (OA) progression... Presented at: 27th Annual Meeting of the American Society for Bone and Mineral Research; September 23-27, 2005; Nashville, Tennessee.
Sunday Sep 25, 2005
Osteoporosis Fractures, Costs Projected to Rise by 50% in 20 Years
A new survey suggests that changing demographics will fuel a 50% increase in the incidence of osteoporotic fractures and associated healthcare costs over the next 20 years... Presented at: 27th Annual Meeting of the American Society for Bone and Mineral Research; September 23-25, 2005; Nashville, Tennessee.
Sunday Sep 25, 2005
Beta-Blockers May Preserve Bone Density and Reduce Fracture Risk
Preliminary results from a new study indicate that use of beta-blockers is associated with a reduction in osteoporotic fractures, higher bone mineral density, better femoral neck geometry, and beneficial effects on trabecular microarchitecture...Presented at: 27th Annual Meeting of the American Society for Bone and Mineral Research; September 23-25, 2005; Nashville, Tennessee.
Sunday Sep 25, 2005
C-Reactive Protein May Help Predict Fracture Risk
A new study provides evidence that circulating levels of C-reactive protein may independently predict fracture risk in postmenopausal women... Presented at: 27th Annual Meeting of the American Society for Bone and Mineral Research; September 23-25, 2005; Nashville, Tennessee.
Saturday Sep 24, 2005
Orthopaedic Surgeons, Neurologists Often Fail to Refer Patients for DEXA Exams
Even with the availability of training programs and educational literature, it is rare for many orthopaedic surgeons and neurologists, physicians who regularly see patients at high risk for fractures, to refer these patients for assessment of bone mineral density (BMD)... Presented at: 27th Annual Meeting of the American Society for Bone and Mineral Research; September 23-25, 2005; Nashville, Tennessee.
Tuesday Sep 20, 2005
Link Between Genetic Factors and Osteoporotic Fractures in the Elderly
The predisposition for osteoporotic fractures is stronger than has been previously estimated, especially for early occurring fractures. A search for genes and gene-environmental interactions that affect early osteoporotic fracture risk is likely to be beneficial, but fracture-prevention should be focused on lifestyle habits...Michaëlsson K, et al. Arch Intern Med. 2005;165:1825-1830.
Monday Aug 08, 2005
Vitamin D Supplements May Not Help African American Women's Bones
Supplementation with vitamin D3 has no effect on bone loss or bone turnover markers in calcium-replete, postmenopausal African American women ... Aloia JF, et al. Arch Intern Med. 2005;165:1618-1623
Thursday Aug 04, 2005
Scientists Develop New Technique to Grow Bone In Vivo
In a development that one day may revolutionize spinal and knee-replacement surgery and the treatment of osteoporosis, researchers at Vanderbilt University in Nashville, Tennessee, have demonstrated for the first time that healthy new bone can be grown in one part of the body to repair bony defects at another location... Stevens MM, et al. In vivo engineering of organs: The bone bioreactor. Proc Natl Acad Sci. 2005; scheduled to appear online before print. Available at: http://www.pnas.org/.
Tuesday Jul 26, 2005
Osteologix's Strontium Formulation in Phase 1 Development for Osteoporosis
Osteologix, Inc., announced that patient enrollment has been completed in its Phase I clinical trial of NBS-101, an improved formulation of strontium for the treatment of osteoporosis.
Thursday Jul 21, 2005
Nastech's Intranasal PTH1-34 Peptide in Phase I for Osteoporosis
Nastech Pharmaceutical Company Inc. of Bothell, Washington, announced the start of a second clinical study to determine the pharmacokinetics and safety of its investigational intranasal human parathyroid hormone (PTH1-34) drug for the treatment of osteoporosis.
Tuesday Jul 12, 2005
Structural Changes in Femoral Neck Increase Risk of Hip Fracture
Walking may not be enough to strengthen the hip; instead, it may be necessary to develop exercises that target the superolateral cortex of the femoral neck, which is often associated with fractures from sideways falls... Mayhew PM, et al. Lancet. 2005;366:129-135.
Monday Jun 27, 2005
Short-Term Use of High Dose Steroids Does Not Increase Fracture Risk
With at least a one-year moratorium on steroid use, short-term, >e;15 mg/day dose of oral glucocorticoids does not increase the risk for osteoporosis or fracture, according the results of a new study... Presented at: 2nd Joint Meeting of the ECTS and the IBMS; June 25-29, 2005; Geneva, Switzerland
Friday Jun 10, 2005
Treatment of RA Reduces Cardiovascular Mortality
Analysis of a large RA database reveals that treatment with MTX or anti-TNF-α drugs causes a significant decrease in mortality, specifically in death due to cardiovascular and pulmonary disease... Presented at: Annual European Congress of Rheumatology of EULAR; June 8-11, 2005; Vienna, Austria.
Monday May 16, 2005
Higher Doses of Vitamin D May Reduce Risk of Fractures in the Elderly
In contrast to several recently published studies showing that regular supplements of calcium and vitamin D may not effectively prevent fractures, a newly published meta-analysis found that large doses of vitamin D-taken with or without calcium-reduce the risk of nonvertebral fractures in the elderly...Bischoff-Ferrari HA, et al. JAMA. 2005;293:2257-2264
Tuesday May 03, 2005
African-American Women Have Lower Risk of Fractures than Caucasians Across All Levels of Bone Mineral Density
New data suggests the need for race specific normative databases to define osteoporosis...Cauley JA, et al. JAMA 2005;293:2102-2108.
Monday May 02, 2005
Vitamin D and Calcium May Not Be Effective for Preventing Fractures
Taken together, two studies suggest an earlier role for antiresorptive drugs in fracture prevention...Grant AM, Anderson FH. Lancet. April 28, 2005; [Epub ahead of print].
Tuesday Apr 26, 2005
EMEA Approves New Spinal Fusion Indication for BMP-2
Wyeth Pharmaceuticals and Astellas Pharma Europe announced that dibotermin alfa/absorbable collagen sponge (rhBMP-2/ACS or InductOs®) received additional marketing authorization from the European Agency for the Evaluation of Medicinal Products (EMEA) for the treatment of single level (L4-S1) anterior lumbar spine fusions as a substitute for autogenous bone graft in adults who have had at least 6 months of nonoperative treatment for degenerative disc disease.
Monday Apr 25, 2005
Novel Osteoinductive Molecule May Speed Fracture Healing and Enhance Spinal Fusion
A newly discovered osteoinductive protein promises greater specificity than bone morphogenetic proteins (BMPs)...UCLA Henry Samueli School of Engineering and Applied Science [press release]. April 21, 2005.
Monday Apr 11, 2005
FDA Approves Alendronate Sodium/Cholecalciferol (Fosamax Plus DR) for Osteoporosis; the Only Bisphosphonate With a Weekly Dose of Vitamin D
Merck & Co, Inc, received marketing approval from the US Food and Drug Administration for its once-weekly tablet containing alendronate sodium (FosamaxR) and vitamin D3 (cholecalciferol) for postmenopausal women with osteoporosis.
Friday Mar 18, 2005
Servier Receives Award for Osteoporosis Drug Strontium Ranelate (ProtelosR)
Servier, the French pharmaceutical company, has received Frost & Sullivan's 2004 Osteoporosis Therapeutics Industry Innovation & Advancement of the Year Award for the development of Protelos (strontium ranelate), a dual-action osteoporosis drug that promotes bone formation by stimulating osteoblasts, and reduces bone resorption by decreasing the osteoclast population.
Friday Mar 18, 2005
Study Suggests Celiac Disease May Be More Prevalent Among Patients with Osteoporosis
New results confirm the value of treating osteoporotic patients with the disease and fuel the debate over the practicality of widespread screening... Stenson WF, et al. Arch Intern Med. 2005;165:393-399.
Wednesday Mar 02, 2005
B-vitamins Help Prevent Hip Fracture In Stroke Patients
Folate and vitamin B12 lower the risk of hip fracture in elderly patients following stroke, possibly due to a reduction in plasma homocysteine levels...Sato Y, et al. JAMA. 2005;293:1082-1088
Thursday Jan 20, 2005
New Bone Imaging Technology May Give DEXA a Run for Its Money on Earth -- and in Space
New ultrasound bone imaging device, which measures bone strength and rate of bone loss as well as bone density, could become the standard for osteoporosis assessment... National Space Biomedical Research Institute, Houston, Texas.
Wednesday Nov 24, 2004
Gender Bias May Exist in the Recognition and Treatment of Osteoporosis in Men
Although men have higher vertebral fracture rates than women, they may not get screening and treatment for osteoporosis as often or as early... Sawka AM, et al. J Rheumatol. 2004;31:1993-1995.
Monday Nov 15, 2004
EPIC Study: Alendronate's Benefits for Osteoporosis Prevention Continue Up to 6 Years
Therapy with the bisphosphonate is effective long-term in preserving bone mineral density in postmenopausal women, and should serve as a promising strategy for the prevention of osteoporosis in the post-HRT era& McClung MR, et al. J Clin Endocrinol Metab. 2004;89:4879-4885.
Wednesday Oct 13, 2004
Significant Advantages Favor Alendronate for Bone Protection
A new trial comparing 2 bisphosphonate formulations finds greater benefits with alendronate vs risedronate and no significant differences between the 2 in reported adverse events, including those associated with upper GI tolerability …Rosen C, et al. J Bone Miner Metab. 2004;19(suppl 1):S94. Abstract F412.
Tuesday Oct 12, 2004
Long-Term Bisphosphonate Therapy Results in Continued Benefits and May Offer Potential for Drug Holiday
Risedronate therapy continued over a 7-year treatment interval might be beneficial and, for some patients, 1 year off therapy may be a reasonable option... Sorensen OH, Crawford GM, Mulder H, et al. Bone . 2003;32:120-126.
Monday Oct 11, 2004
Vitamin D Deficiency May Diminish Effectiveness of Osteoporosis Therapy
Recently released clinical trials data underscore the impact of vitamin D deficiency in at-risk populations, and the importance of the vitamin in strengthening the effects of osteoporosis therapy... Holick MF, et al. J Bone Miner Metab. 2004;19 (suppl 1):S342. Abstract SU583.
Thursday Oct 07, 2004
Emerging Role of Bone Turnover Markers in Clinical Management of Osteoporotic Patients
According to a leading authority at the annual meeting of The American Society for Bone and Mineral Research, markers of bone turnover can be a potentially valuable component of the overall management strategy for osteoporosis... (Johnell O, et al. Osteoporos Int. 2002;13:523-526; Eastell R, et al. J Bone Miner Res. 2003;18:1051-1056.)
Tuesday Oct 05, 2004
New Focus on Osteoporosis Risk in Men
Until recently, osteoporosis, a known health risk in postmenopausal women, has attracted scant attention as a health risk for men. Although men and women alike benefit from treatment for osteoporosis, men receive treatment far less frequently, even after fractures.
Wednesday Jul 14, 2004
Use of Anti-epileptic Drugs Associated with Increased Bone Loss in Older Women
A recent study of over 9000 women suggests that those taking anti-epileptic drugs may have an increased risk of osteoporosis.
|
